Propanc Biopharma, Inc. (PPCB) News
Follow Propanc Biopharma, Inc. (PPCB) news in one place: company catalysts, earnings, analyst actions and wider market developments. Review 12 public stories across 10 publication days to understand how the story developed. Public news appears after a 15-minute delay; LiveCast subscribers can follow new headlines and hear important updates without this additional delay.
L
Propanc Biopharma, Inc. (PPCB) Plans Q1 2027 Phase 1b PRP Trial; Raises $7.5M, Starts $5M Buyback
Propanc Biopharma reported $7.5M gross proceeds for FY25-26, began a $5.0M share repurchase program, and plans to start a Phase 1b first-in-human PRP study in Q1 2027 enrolling up to 50 advanced solid tumor patients.Mate
NEWS | Sep 29, 2026, 12:33 PM UTC
L
Propanc Biopharma Provides Corporate Update & Year-End June 30, 2025-26, Financial Results
Plans To Commence World-First Phase 1b First-In-Human (FIH) Study of PRP Q1, 2027MELBOURNE, Australia, Sept. 29, 2026 (GLOBE NEWSWIRE) -- Propanc Biopharma, Inc. NASDAQ:PPCB (“Propanc” or the “Company”), a biopharmaceuti
EARNINGS | Sep 29, 2026, 12:32 PM UTC
L
Propanc Biopharma, Inc. FY 2026: Revenue $0 EPS $(17.62) — 10-K Summary
Propanc Biopharma, Inc. reported fiscal 2026 results as a development-stage company, with no revenue and a reduced net loss versus the prior year. Revenue was $0 in both FY 2026 and FY 2025, and the net loss available to
EARNINGS | Sep 25, 2026, 09:27 PM UTC
L
PPCB - Propanc Biopharma Highlights Differentiated PRP Pancreatic Cancer Data Versus Emerging Pan-RAS Program ERAS-0015
PPCB - Propanc Biopharma Highlights Differentiated PRP Pancreatic Cancer Data Versus Emerging Pan-RAS Program ERAS-0015
NEWS | Sep 22, 2026, 12:30 PM UTC
L
PPCB - Propanc Biopharma Positions PRP’s EMT-Reversal Mechanism as a Complementary Backbone to Emerging RAS Inhibitors from Revolution Medicines, Inc. and Erasca, Inc.
PPCB - Propanc Biopharma Positions PRP’s EMT-Reversal Mechanism as a Complementary Backbone to Emerging RAS Inhibitors from Revolution Medicines, Inc. and Erasca, Inc.
NEWS | Sep 16, 2026, 12:30 PM UTC
L
Propanc Biopharma to start Phase 1b first-in-human PRP study in Feb 2027
Propanc Biopharma said it will initiate a Phase 1b first-in-human study of PRP in February 2027.
EQUITY | Sep 09, 2026, 12:32 PM UTC
L
Propanc Biopharma announces new preclinical pancreatic cancer data
Propanc Biopharma said PRP preclinical results showed >90% tumor growth inhibition and >2.5-fold survival benefit in pancreatic cancer.
EQUITY | Aug 27, 2026, 12:37 PM UTC
M
Propanc Biopharma clears path for Phase 1b clinical study
Propanc Biopharma (PPCB) clears the path for a world-first Phase 1b clinical study of a cancer therapy, according to TradeXchange Newsdesk.
EQUITY | Aug 18, 2026, 12:30 PM UTC
L
PPCB Highlights PRP Therapy
PPCB highlights PRP as a potential therapy for RAS-driven cancers
EQUITY | Aug 12, 2026, 12:31 PM UTC
H
Propanc Biopharma Reports Positive PRP Data
Propanc Biopharma reports positive PRP preclinical data
EQUITY | Aug 06, 2026, 12:31 PM UTC
L
Propanc Biopharma shares are trading higher after the company announced it has initiated a share repurchase program authorizing the company
Propanc Biopharma shares are trading higher after the company announced it has initiated a share repurchase program authorizing the company to repurchase a first tranche of up to $500,000 over the next 30-day period.
EQUITY | Jul 02, 2026, 03:14 PM UTC
L
Propanc Biopharma Initiates First Tranche Of $500K Stock Buyback Plan
Propanc Biopharma, Inc. (NASDAQ: PPCB ) ("Propanc" or the "Company"), a biopharmaceutical company focused on developing novel treatments for chronic diseases, including recurrent and metastatic cancer, today announced it
EQUITY | Jul 02, 2026, 12:31 PM UTC